April 18, 2007 |
March 25, 2009 |
April 2007 |
Safety, tolerability, and maximum tolerated dose of once-weekly and/or twice-weekly 1-hour intravenous (IV) infusion of XL228 [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: Yes ] |
Same as current |
Complete list of historical versions of study NCT00464113 on ClinicalTrials.gov Archive Site |
- Evaluate plasma pharmacokinetics and estimate renal elimination of once-weekly and twice-weekly 1-hour IV infusion of XL228 [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: No ]
- Exploratory Outcomes: Evaluate hematologic and cytogenetic response and pharmacodynamic correlates of XL228 activity [ Time Frame: Assessed at periodic visits ] [ Designated as safety issue: No ]
|
- Evaluate plasma pharmacokinetics and estimate renal elimination of a single 1-hour IV infusion of XL228
- Exploratory Outcomes: Evaluate hematologic and cytogenetic response and pharmacodynamic correlates of XL228 activity in plasma after repeated weekly
administration of XL228
|
|
Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia |
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL228 Administered Intravenously to Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia (Ph+ ALL) |
The purpose of this study is to determine the safest dose of the BCR-ABL inhibitor XL228, how often it should be taken, and how well people with leukemia tolerate XL228. |
|
Phase I |
Interventional |
Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
- Chronic Myeloid Leukemia
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
|
Drug: XL228 |
- Experimental: once-weekly dosing
- Experimental: twice-weekly dosing
|
|
|
Recruiting |
100 |
|
April 2009 (final data collection date for primary outcome measure) |
Inclusion Criteria:
The subject has a confirmed pathologic diagnosis as evidenced by the presence of the BCR-Abl translocation [t(9;22)] by fluorescence in situ hybridization (FISH), cytogenetics, or quantitative polymerase chain reaction (QPCR) of one of the following:
CML
- Chronic phase (CP)
- Accelerated phase (AP)
- Blast phase (BP) OR
- Ph+ ALL
The subject has one of the following:
- Known T315I Abl mutation
- Known resistance to or intolerance of imatinib and dasatinib
- At least one prior anti-leukemia therapy, including, but not limited to, interferon, imatinib, or dasatinib
- The subject is at least 18 years old.
- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
- The subject has adequate organ function.
- The subject is capable of understanding and complying with the protocol and has signed the informed consent document.
- Sexually active subjects must use an accepted method of contraception during the course of the study.
- Female subjects of childbearing potential must have a negative pregnancy test at enrollment.
Exclusion Criteria:
- The subject has received interferon, imatinib, or dasatinib within 7 days of the first dose of XL228.
- The subject has received an investigational agent or radiotherapy within 28 days of the first dose of XL228.
- The subject has received immunosuppressive therapy (eg, cyclosporine, steroids, tacrolimus for graft-versus-host disease [GVHD]) within 28 days prior to the first dose of XL228.
- The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤1 from toxicities related to peripheral stem cell or bone marrow transplant.
- The subject has not recovered to CTCAE v3.0 Grade ≤1 from adverse events (AEs) due to investigational drugs or other medications.
- The subject has known allergy or hypersensitivity to any component of the investigational drug product.
- The subject has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- The subject is pregnant or breastfeeding.
- The subject is known to be positive for the human immunodeficiency virus (HIV).
- The subject has an inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee.
|
Both |
18 Years and older |
No |
Contact: Exelixis Contact Line |
1-866-939-4041 |
|
|
|
United States |
|
|
NCT00464113 |
Paul Woodard, MD/Director, Clinical Research, Exelixis, Inc. |
|
Exelixis |
|
|
Exelixis |
March 2009 |